新型及旧型单株抗体药物治疗慢性淋巴细胞白血病。

New and old monoclonal antibodies for the treatment of chronic lymphocytic leukemia.

机构信息

Hematology Department, Catholic University of Sacred Hearth, Largo Agostino Gemelli, 00168 Rome, Italy.

出版信息

Mini Rev Med Chem. 2011 Jun;11(6):508-18. doi: 10.2174/138955711795843374.

Abstract

Over the last few years, several new agents have been under evaluation in preclinical studies and clinical trials, showing promise in treating chronic lymphocytic leukemia (CLL). Among these agents, monoclonal antibodies (mAbs) such as rituximab and alemtuzumab have changed the natural course of the disease. Nowadays there are several new promising monoclonal antibodies under investigation against the CD20, CD23, CD37 and CD40 molecules. Application of newer monoclonal antibodies represents an area of ongoing clinical research in CLL.

摘要

在过去的几年中，有几种新的药物在临床前研究和临床试验中进行了评估，显示出在治疗慢性淋巴细胞白血病（CLL）方面的潜力。在这些药物中，单克隆抗体（mAbs）如利妥昔单抗和阿仑单抗改变了疾病的自然进程。目前，有几种针对 CD20、CD23、CD37 和 CD40 分子的新型单克隆抗体正在研究中，具有很大的应用前景。新型单克隆抗体的应用是 CLL 正在进行的临床研究领域。